48 results about "Anti hyperglycemic" patented technology

Sustained release pharmaceutical formulations comprising an antihyperglycemic drug or a pharmaceutically acceptable salt thereof are disclosed. The formulations provide therapeutic plasma levels of the antihyperglycemic drug to a human patient over a 24 hour period after administration.

A controlled release antihyperglycemic tablet that does not contain an expanding polymer and comprising a core containing the antihyperglycemic drug, a semipermeable membrane coating the core and at least one passageway in the membrane.

The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and / or atherosclerosis.

A pharmaceutical agent having GPR40 receptor agonistic action, particularly a compound which is useful as an insulin secretagogue or an agent for preventing and / or treating diabetes mellitus. The present inventors have examined a compound having GPR40 receptor agonistic action, confirmed that an oxadiazolidinedione compound which has a substituent such as a benzyl group, etc. linked with a substituent such as a phenyl group, etc. through a linker at the 2-position of an oxadiazolidinedione ring, or a pharmaceutically acceptable salt thereof has an excellent GPR40 agonistic activity, and thus completed the invention. The oxadiazolidinedione compound has excellent insulin secretagogue action and anti-hyperglycemic action, and therefore can be used as an insulin secretagogue or an agent for preventing and / or treating diabetes mellitus.

The present invention is in the fields of medicine, pharmaceuticals, nutraceuticals, endocrinology and cardiology. The invention provides compositions comprising a statin, an inhibitor of the angiotensin converting enzyme, an antiplatelet compound and an anti-hyperglycemic compound for use in the treatment and / or prevention of cardiometabolic risk factors of Metabolic Syndrome and treatment and / or prevention of Metabolic Syndrome. The present invention provides for the use of such compositions in the manufacture of products for treatment and / or prevention of Metabolic Syndrome. The biguanide metformin of the composition could be present in extended release form allowing its use together with the other drugs in a single dosage form at low dose. This combination of drugs in a single daily dosage greatly improves compliance and adherence to treatment which is a critical factor for treating patients with Metabolic Syndrome.

Disclosed is the preparation and pharmaceutical use of substituted arylalcanoic acid derivatives of Formula I, wherein ring A, ring B, R1, R2, R3, R4, R5, X, Alk1, Alk2, Ar1, and Ar2 are as defined in the specification. These compounds, as selective agonists activating peroxisome proliferator-activated receptors (PPAR), in particularly the RXR / PPARalpha, RXR / PPARgamma, and RXR / PPARdelta heterodimers, are useful in the treatment and / or prevention of type 2 diabetes and associated metabolic syndrome such as hypertension, obesity, insulin resistance, hyperlipidemia, hyperglycemia, hypercholesterolemia, atherosclerosis, coronary artery disease, and other cardiovascular disorders with improved side effects profile commonly associated with conventional PPARgamma agonists.

The invention relates to a method for preparing black edible fungus anti-hyperglycemic product, belonging to field of preparing polysaccharide. The invention employs black edible fungus deep level liquid fermentation technique, extracts inter-cellular and extra-cellular polysaccharide from deep level fermentation culture, and getting final product through preparation with cell wall-broken treated black edible fungus powder. The product is characterized by apparent functions of reducing serum cholesterol, triglyceride and low-density lipoprotein, and can be used for subsidiary treatment or prevention for hyperlipoidemia.

A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.

The present invention is in the fields of medicine, pharmaceuticals, nutraceuticals, endocrinology and cardiology. The invention provides compositions comprising a statin, an inhibitor of the angiotensin converting enzyme, an antiplatelet compound and an anti-hyperglycemic compound for use in the treatment and / or prevention of cardiometabolic risk factors of Metabolic Syndrome and treatment and / or prevention of Metabolic Syndrome. The present invention provides for the use of such compositions in the manufacture of products for treatment and / or prevention of Metabolic Syndrome. The biguanide metformin of the composition could be present in extended release form allowing its use together with the other drugs in a single dosage form at low dose. This combination of drugs in a single daily dosage greatly improves compliance and adherence to treatment which is a critical factor for treating patients with Metabolic Syndrome.

The present invention provides novel substituted chalcone derivatives which exhibit anti-hyperglycemic and anti-dyslipedemic activity. The invention also provides a method for treating type II diabetes and associated hyperlipidemic conditions in a mammal by administering the compounds of the present invention and compositions containing these derivatives.

This invention provides a-glucosidase inhibitors isolated from Oroxylum indicum an Indian medicinal plant. Particularly, this invention provides hexane and acetone fraction of Oroxylum indicum wherein the hexane fraction comprises a-glucosidase active compounds of oroxylin A, chrysin and baicalain and acetone fraction comprises the compounds of oroxylin A, chrysin, baicalain, methoxy chrysin and oroxyloside methyl ester. This invention also relates to a process for the isolation of a-glucosidase inhibitory active compounds from the above said hexane and acetone fraction of Oroxylum indicum. This invention also provides the use of potent intestinal a-glucosidase inhibitors as active ingredients that can be used in pharmaceuticals, food products, health foods and specialized health care foods as anti hyperglycemic agent for prevention and treatment of post prandial hyperglycemia, hyperglycemia and related conditions in diabetes mellitus, obesity and disease conditions requiring hyperglycemic control as well as inhibition of a-glucosidase activity.

A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a angiotensin antagonist is herein disclosed and described.

The invention provides a diabetes full-nutrition formula food and a preparation method thereof. The formula food comprises maltodextrin, resistant dextrin, xylitol, fruit and vegetable powder, gingerpowder, soy isolate protein, whey protein, vegetable fat powder, inulin, fructo-oligosaccharide, konjaku flour, probiotic powder, retinyl acetate, vitamin D3 powder, D-alpha-tocopheryl acetate powder,vitamin K1, thiamine hydrochloride, riboflavin, pyridoxine hydrochloride, cyanocobalamin, nicotinamide, folic acid, D-calcium pantothenate, L-sodium ascorbate, D-biotin, copper sulfate, magnesium sulfate, ferrous sulfate, zinc citrate, manganese sulfate, calcium hydrophosphate, potassium iodide, sodium selenite and potassium chloride. The diabetes full-nutrition formula food is rich in nutrition,can improve the microenvironment in the body of a patient, can resist oxidative stress of hyperglycemia on the body, and reduces body injury. The preparation method of the formula food has the advantages that the process is simple and easy to control and the formula food is suitable for wide popularization.

The invention discloses a sulfonamide compound and a preparation method as well as application thereof, and provides the sulfonamide compound with hypoglycemic activity and the preparation method thereof. The sulfonamide compound has a structure of a general formula I, wherein X is S or O atoms, n is 1, 2, 3 or 4, R1 and R2 are simultaneously or respectively hydrogen or C1-C4 alkyl groups, and R3, R4 and R5 are simultaneously or respectively one out of hydrogen, C1-C6 alkyl groups, C1-C4 alkoxyl groups, halogens, single or multi-halogen replaced C1-C4 alkyl groups, cyan, phenyl groups, single halogenated phenyl groups, C1-C4 alkoxyl phenyl group, C1-C4 alkyl sulfonyl groups and bromomethyl carbonyl groups. The sulfonamide compound with the structure of the formula I and pharmaceutically acceptable salts thereof have obvious effect in terms of resisting hyperglycemia.

Selected diabetic patients reveal significant glycemic control after bariatric surgical or endoscopic duodenal bypass. This controlling effect appears to occur partly because of an enhanced Glucagon-Like Peptide 1 (GLP1) release from intestinal L-cells. These procedures may also cause complications such as nutritional deficiencies. The present invention provides a stent. The method that places this stent in the ileum to activate the endogenous GLP1 release is a safer alternative to control the diabetes mellitus. However, the less mobile wall of the ileum next to the proximal stent rim can trigger an unwanted telescoping of the intestine, which is known as intussusception. An embodiment of this invention illustrates the characteristics of a stent that can prevent a likely intussusception and consequently be more confidently applied in the ileum to maintain or restore the ileal patency in general or for its anti-hyperglycemic effect in particular.

The invention discloses a traditional Chinese medicine prescription anti-hyperglycemic calculi-dissolving oral liquid and process for preparation. Firstly, walnut kernel, sesame seed, pinenut, and hemp seed are extracted, and the grease is further stored for standby, secondly, nucleolus is extracted, the grease is stored for standby, the oil cake is dipped with grain alcohol, and is filtered, and the grain alcohol is recovered from the filter liquid and the filter liquid is condensed, thirdly, the extract oils of the walnut kernel, the sesame seed, the pinenut, and the hemp seed, the nucleolusl oil, the extract liquid of the nucleolusl oil cake, and bee honey are mixed, churned, and are hermitically encapsulated and disinfected. The invention can evidently improve bile salt density in a liner, and can evidently improve the effect of lecithine density in a liner, and has the effects of evidently reducing blood fat, dissolving and discharging calculi, curing coronary disease, and reducing pressure, and is beneficial to gallbladder.

The invention relates to the technical field of protein extraction. In order to solve the problem that a large amount of by-products are generated during processing of Nibea japonica and the resourceutilization rate is low, the invention provides a preparation method of dipeptidyl peptidase-IV inhibitory peptide derived from collagen of swim bladder of Nibea japonica. The method comprises the following steps: (1) pretreating swim bladder of Nibea japonica, then extracting collagen with 5 wt% acetic acid combined with pepsin, and carrying out centrifugal drying to obtain collagen of swim bladder of Nibea japonica; (2) carrying out enzymolysis on the collagen of swim bladder of Nibea japonica by the use of compound enzyme so as to obtain collagen peptide of swim bladder of Nibea japonica; and (3) screening a kit by combining the collagen peptide of swim bladder of Nibea japonica with dipeptidyl peptidase so as to obtain the dipeptidyl peptidase-IV inhibitory peptide. With the swim bladder of Nibea japonica as the main raw material and through an efficient technology, the dipeptidyl peptidase-IV inhibitory peptide is prepared. The inhibitory peptide has a good effect of inhibiting dipeptidyl peptidase-4, and has a good anti-hyperglycemic effect.

An amide derivative represented by the following formula: wherein the ring B is a heteroaryl group; X is a bond or a lower alkylene group; and R is a hydrogen atom, a halogen atom, a lower alkyl group, an amino group, an aryl lower alkyl group or a haloaryl lower alkyl group, or a salt thereof, is disclosed. A therapeutic agent for diabetes mellitus having both an insulin secretion promoting action and an insulin sensitivity potentiating action and also having anti-obesity and anti-hyperlipemia actions due to a selective stimulating action to beta3-receptors, is also disclosed.

A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative and a disintegrating agent is herein disclosed and described. The dosage formulation exhibits a significant increase in bioavailability of the thiazolidinedione derivative component compared to conventional immediate release dosage forms containing only a thiazolidinedione derivative.

Provided is a method of hydrogenating the exocyclic double bond of a thiazolidinedione precursor in a method of making a thiazolidinedione antihyperglycemic, for example pioglitazone, including work-up steps to afford pure thiazolidinedione antihyperglycemic.

Compositions including anti hyperglycemic agents from Portulaca oleracea L. are provided. Also provided are methods of isolating such anti hyperglycemic agents and methods of using same.

The invention discloses anti-hyperglycemic drug and a preparing method thereof. The anti-hyperglycemic drug is made from coix seed, Chinese yam, astragalus root, desertliving Cistanche, fleeceflower root, honeysuckle, mulberry leaf, mulberry, chrysanthemum and wolfberry fruit according to a certain weight ratio. The anti-hyperglycemic drug has the effects of tonifying liver and kidney, inducing diuresis to alleviate edema, removing heat to cool blood and nourishing yin to promote salvia, is applicable to treatment of hyperglycemia and acts quick, with short process and no toxic or side effects.

The present invention relates to pentose and pentose derivatives that are effective at increasing glucose transport in a non-insulin dependent manner, and to uses thereof for a) treating and / or preventing hyperglycemia; b) treating and / or preventing the complications of hyperglycemia; c) treating diabetes; d) increasing the rate of cellular glucose transport; e) increasing the rate of cellular glucose uptake; f) improving the ability of a subject to metabolize glucose; g) treating daily blood glucose fluctuations; h) reducing blood sugar levels; i) reducing the dosage of anti-diabetic medication needed for treatment of diabetes. The present invention further provides novel pentose derivatives having beneficial properties in terms of pharmacokinetics, to pharmaceutical compositions comprising these novel compounds and uses thereof.

The present invention relates to a novel hypoglycemic / anti-hyperglycemic protein named ADMc1 purified from the seeds of Momordica charantia for control of hyperglycemia. The process for the purification of novel hypoglycemic / anti-hyperglycemic protein named ADMc1 is also disclosed. The invention also relates to process for preparation and purification of the recombinant novel hypoglycemic / anti-hyperglycemic protein of Momordica charantia, named rADMc1. Both ADMc1 and rADMc1 are highly effective and need to be administered only once a day to maintain normal blood glucose levels. The procedure involves purification of a novel hypoglycemic / anti-hyperglycemic protein of M. charantia, construction of cDNA library from M. charantia seeds, screening of cDNA library using oligonucleotide probe designed on the basis of amino acid sequence of the tryptic fragment of the protein, cloning of the cDNA in a eukaryotic expression system, expression and purification of the recombinant protein.

The invention relates to the technical field of food processing, and discloses anti-hyperglycemic steamed buns. The steamed buns are characterized by being prepared from raw materials with the following parts by weight: 100 parts of flour, 7-10 parts of bitter gourd powders, 5-7 parts of maize flour, 5-7 parts of green bean powders, 3-5 parts of wolfberry powders, 0.7-0.8 part of yeast, and 55-65parts of cold water. The steamed buns are prepared as follows: grinding the raw materials; preparing mixed powders; preparing fermented dough; carrying out kneading to obtain mixed dough; preparing round unsteamed buns; steaming the round unsteamed buns; and obtaining the anti-hyperglycemic steamed buns. The anti-hyperglycemic steamed buns disclosed by the invention have the beneficial effects that the steam buns taste good, have multiple effects such as reducing blood glucose, promoting gland activities, tonifying the kidney, enriching the essence, nourishing the liver to improve the eyesight, encouraging the secretion of saliva to quench thirst and the like, can effectively enhance the human immunity, and achieve an effective dietary function for diabetes and high blood and urine glucoselevels.

Novel methods of using thiazolidinone derivatives and related antihyperglycemic agents to treat populations experiencing impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus (NIDDM) and complications arising thereform are disclosed.

Disclosed is a sphingomyelin-containing material which can be produced in a large quantity at low cost. Also disclosed is an useful use application of a sphingomyelin-containing material. Specifically disclosed is an anti-hyperglycemic and / or anti-hyperlipidemic agent comprising a material containing a sphingomyelin derived from an avain skin as an active ingredient.

The invention relates to a synthetic process of an anti-hyperglycemic drug intermediate R-3-amino-piperidine dihydrochloride. The synthetic process comprises the steps: using inexpensive L-glutamic acid as a starting material, and performing esterification, amino protection, reduction, hydroxyl protection, substitution, cyclization and removal of protecting groups for amino groups so as to obtainthe R-3-amino-piperidine dihydrochloride. Compared with the prior art, the synthetic process has cheap and easily available raw materials, good selectivity, good atomic economy, high total yield and mild reaction conditions, and is suitable for industrial production.

Disclosed are the preparation and pharmaceutical use of novel noncyclic 1,3-dicarbonyl compounds of formula I, wherein ring A, ring B, R1, R2, R3, R4, R5, X, Y, Z, Q, Ar and n are as defined in the specification. These compounds, as peroxisome proliferator-activated receptor (PPAR) dual agonists for both RXR / PPARgamma and RXR / PPARalpha heterodimers, are useful in the treatment and / or prevention of type 2 diabetes and associated metabolic syndrome such as hypertension, obesity, insulin resistance, hyperlipidemia, hyperglycemia, hypercholesterolemia, atherosclerosis, coronary artery disease, and other cardiovascular disorders

The invention relates to the technical field of protein extraction. In order to solve the problem of a large number of by-products and low resource utilization in the processing of Japanese croaker, a method for preparing a biological source dipeptidyl peptidase-IV inhibitor is provided, comprising the following steps: Steps: (1) pretreating the skin of Japanese yellow croaker to obtain skin powder, then extracting collagen from the fish skin powder, and centrifuging and drying to obtain skin collagen of Japanese yellow croaker; (2) using compound enzymes to process ( 1) enzymatic hydrolysis of the obtained Japanese croaker skin collagen to obtain the Japanese croaker skin collagen peptide; (3) screening the Japanese croaker skin collagen peptide with a dipeptidyl peptidase screening kit, namely Obtain biological source dipeptidyl peptidase-IV inhibitor. In the present invention, the dipeptidyl peptidase-IV inhibitory peptide is prepared by using the skin of Japanese yellow croaker fish as the main raw material through a relatively efficient process. Good anti-hyperglycemic effect.